A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C. [electronic resource]
Producer: 20030725Description: 131-6 p. digitalISSN:- 1466-4860
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- administration & dosage
- Dose-Response Relationship, Drug
- Drug Resistance, Multiple
- Female
- Hematologic Neoplasms -- drug therapy
- Humans
- Lymphocyte Count
- Lymphoproliferative Disorders -- drug therapy
- Male
- Middle Aged
- Protein Kinase C -- antagonists & inhibitors
- Staurosporine -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.